+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Myocardial Infarction (MI) Therapeutics Market 2019-2023 - Product Image

Global Myocardial Infarction (MI) Therapeutics Market 2019-2023

  • ID: 4751583
  • Report
  • Region: Global
  • 128 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bayer AG
  • Eli Lilly and Company
  • Pfizer
  • MORE
MI along with other cardiovascular problems, is the leading cause of premature deaths in the world. The rising incidence of coronary artery disease, obesity, diabetes, and hypertension, along with a sedentary lifestyle, smoking, and reduced physical activities, is expected to increase the risk factors for cardiovascular diseases including MI. Apart from these factors, the rapid rise in the geriatric population is increasing the incidence of MI. Hence, the incidence of MI is expected to increase with the rapidly expanding geriatric population. The rising incidence of MI will propel the growth of the market during the forecast period. The analysts have predicted that the myocardial infarction (MI) therapeutics market will register a CAGR of almost 3% by 2023.

Market Overview

Increased adoption of novel antithrombotics

Novel antithrombotics such as NOACs and antiplatelet drugs (BRILINTA and Effient) possess the potential to expand the scope of the treatment for MI. These drugs offer significant advantages such as target specificity. The market also contains specific antidotes for these drugs, which can help prevent life-threatening or uncontrolled bleeding.

Extensive use of generics

A generic drug is a medication that is the same as the existing approved branded drug in terms of dosage form, safety, strength, route of administration, quality, and performance characteristics. Generic drugs are allowed for sale after the expiry of the patent of the original branded drug. Thus, generic drugs have comparatively lower prices than the branded drugs.

For the detailed list of factors that will drive and challenge the growth of the myocardial infarction (MI) therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bayer AG
  • Eli Lilly and Company
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Antithrombotics - Market size and forecast 2018-2023
  • Vasodilators - Market size and forecast 2018-2023
  • Thrombolytics - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE
  • MI type
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Stem cell therapies for MI
  • Advanced diagnostic modalities for MI
  • Rising number of patient-support initiatives
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Pfizer Inc.
PART 16: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global cardiovascular disorder treatment market
Exhibit 02: Segments of global cardiovascular disorder treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for MI
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antithrombotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antithrombotics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Vasodilators - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Vasodilators - Year-over-year growth 2019-2023 (%)
Exhibit 24: Thrombolytics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Activase sales in $ million
Exhibit 26: Thrombolytics - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Repatha sales $ million
Exhibit 29: Others - Year-over-year growth 2019-2023 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Market share by geography 2018-2023 (%)
Exhibit 33: Geographic comparison
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Sales of NOACs during 2015-2017 in $ million
Exhibit 45: Patent expiration dates of approved branded drugs for MI
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Stem cell therapies for MI
Exhibit 48: Patient support programs
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: AstraZeneca - Vendor overview
Exhibit 55: AstraZeneca - Business segments
Exhibit 56: AstraZeneca - Organizational developments
Exhibit 57: AstraZeneca - Geographic focus
Exhibit 58: AstraZeneca - Key offerings
Exhibit 59: Bayer AG - Vendor overview
Exhibit 60: Bayer AG - Business segments
Exhibit 61: Bayer AG - Organizational developments
Exhibit 62: Bayer AG - Geographic focus
Exhibit 63: Bayer AG - Segment focus
Exhibit 64: Bayer AG - Key offerings
Exhibit 65: Bristol-Myers Squibb Company - Vendor overview
Exhibit 66: Bristol-Myers Squibb Company - Business segments
Exhibit 67: Bristol-Myers Squibb Company - Organizational developments
Exhibit 68: Bristol-Myers Squibb Company - Geographic focus
Exhibit 69: Bristol-Myers Squibb Company - Key offerings
Exhibit 70: Eli Lilly and Company - Vendor overview
Exhibit 71: Eli Lilly and Company - Business segments
Exhibit 72: Eli Lilly and Company - Organizational developments
Exhibit 73: Eli Lilly and Company - Geographic focus
Exhibit 74: Eli Lilly and Company - Segment focus
Exhibit 75: Eli Lilly and Company - Key offerings
Exhibit 76: Pfizer Inc. - Vendor overview
Exhibit 77: Pfizer Inc. - Business segments
Exhibit 78: Pfizer Inc. - Organizational developments
Exhibit 79: Pfizer Inc. - Geographic focus
Exhibit 80: Pfizer Inc. - Segment focus
Exhibit 81: Pfizer Inc. - Key offerings
Exhibit 82: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bayer AG
  • Eli Lilly and Company
  • Pfizer
  • MORE
global myocardial infarction (MI) therapeutics market 2019-2023

The analyst recognizes the following companies as the key players in the global myocardial infarction (MI) therapeutics market: AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising number of patient- support initiatives.”

According to the report, one of the major drivers for this market is the availability of such reimbursement schemes is contributing to the growth of the market.

Further, the report states that one of the major factors hindering the growth of this market is the patient propensity toward substitutes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll